Regenxbio Inc
General
Total Cases6
Active Cases1
Patents4
Ratings
Experience
Grade
Trend
DCT
--
--
--
PTAB
L3
C
CAFC
--
--
--
Analytics
Cases
Litigated Patents
Ratings Trends
Recent Dockets
Entered | Case | Description |
|---|---|---|
| 08/22/24 | The following patents were Not Instituted by PTAB:
Patent US11680274 in IPR2024-00580 | |
| 03/20/24 | ORDER: The case is ADMINISTRATIVELY CLOSED. The parties shall promptly notify the Court when the PTAB action has been resolved so that this case may be reopened and other appropriate action may be taken. Signed by Judge Richard G. Andrews on 3/20/2024. (nms) (Entered: 03/20/2024) | |
| 03/20/24 | SO ORDERED Granting 40 Joint Stipulation and Proposed Order to Stay. Signed by Judge Richard G. Andrews on 3/20/2024. (nms) (Entered: 03/20/2024) | |
| 03/19/24 | Joint Stipulation and [Proposed] Order to Stay, by REGENXBIO Inc.. (Morrison, Susan) Modified on 3/19/2024 (nms). (Entered: 03/19/2024) | |
| 03/04/24 | REDACTED VERSION of 248 Declaration of Mark Murphy in Support of Unopposed Motion to Redact December 6, 2023 Transcript by REGENXBIO Inc.. (Morrison, Susan) (Entered: 03/04/2024) | |
| 03/04/24 | REDACTED VERSION of 247 Unopposed Motion to Redact Transcript by REGENXBIO Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Text of Proposed Order)(Morrison, Susan) (Entered: 03/04/2024) | |
| 03/04/24 | REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of redacted versions of DI # 247 and 248 . (nms) (Entered: 03/04/2024) | |
| 02/28/24 | NOTICE OF SERVICE of Defendants' Initial Invalidity Contentions - filed by Catalent Inc., Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 02/28/2024) | |
| 02/22/24 | ORAL ORDER: The Court has considered the motion and the declaration. (D.I. 247 , D.I. 248 ). Despite the references in both the motion and the declaration to specific terms of confidential agreements, the actual description during the argument (D.I. 247-1 Ex. A at 80, 82) was in general and often broad terms. True, Plaintiffs requested redactions are modest and not unreasonable, but I am unconvinced that disclosure that some of RegenXBios licensing agreements including such things as modest up-front payments, the possibility of renegotiating an agreement if there was change of control, or all sorts of rights for worldwide use, would reveal any trade secrets or the equivalent or otherwise put RegenXBio at a competitive disadvantage in future licensing negotiations. The motion (D.I. 247 ) is DENIED. Ordered by Judge Richard G. Andrews on 2/22/2024. (nms) (Entered: 02/22/2024) | |
| 02/21/24 | [SEALED] Declaration re 247 Unopposed Motion to Redact Transcript, by REGENXBIO Inc.. (Morrison, Susan) Modified on 2/22/2024 (nms). (Entered: 02/21/2024) |